Moffitt Onco Update

Veliparib Monotherapy Study Suggests Benefits for Advanced HER2 Negative Breast Cancer Patients

June 01, 2020

Breast Tumor

Dr. Hyo (Heather) HanResearch Director and medical oncologist in Moffitt's Breast Cancer Oncology Department, presented the results of the BROCADE3 study at ASCO 2020. BROCADE3, a phase III study, investigates the use of Veliparib monotherapy (a PARP inhibitor) following combination therapy with Veliparib+ carboplatin/paclitaxel in patients with germline BRCA-associated advanced breast cancer.

Dr. Heather Han, Research Director, Breast Cancer Oncology Department

The study included 590 randomized patients who received either Veliparib monotherapy or a placebo in a 2:1 ratio to determine the safety and efficacy of Veliparib monotherapy following Veliparib combined with chemotherapy. The analysis suggests that the overall progression free survival benefit comes from Veliparib monotherapy with a combination of carboplatin/paclitaxel and from continued Veliparib treatment after discontinuing chemotherapy prior to disease progression. Therefore, Veliparib may be a suitable treatment following the use of combination chemotherapy for a limited duration.

View the abstract and poster for more information about the BROCADE3 study. The trial is active, but not currently recruiting participants.

To learn more about breast cancer clinical trials or to refer a patient, complete our online form or contact a physician liaison for assistance or support.  As part of our efforts to shorten referral times as much as possible, online referrals are typically responded to within 24 - 48 hours.